Headquartered in Princeton, NJ Fiscal year ends December NASDAQ: IART integralife.com
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a global medical technology company focused on neurosurgery, tissue reconstruction, and specialized surgical fields. The company operates through two segments: Codman Specialty Surgical, which includes neurosurgery products (such as CereLink monitoring, Mayfield cranial stabilization, Aurora surgical tools, and CUSA ultrasonic aspirators), instruments, and ENT products (including AERA sinus dilation, TruDi navigation, and MicroFrance instruments); and Tissue Technologies, which encompasses wound reconstruction and care products (including Integra Skin, PriMatrix, Durepair, and MediHoney) as well as private-label tissue processing. The company serves healthcare professionals globally with differentiated medical devices and regenerative technologies used in surgical procedures, trauma care, and wound management. Integra is currently executing a multi-year quality remediation and compliance master plan following a voluntary recall of products manufactured at its Boston facility, while also pursuing structural optimization and EU Medical Device Regulation compliance. Updated
With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets. Healthcare keeps that promise.…
With a market rotation underway, where should investors seeking opportunities in health care be looking? Analysts have high expectations for Alphatec.
Friday's top analyst upgrades and downgrades included Abercrombie & Fitch, Amazon.com, AMC Entertainment, Analog Devices, Discover Financial Services, Estee Lauder, Foot Locker, International Flavors & Fragrances, NetApp, Nvidia, Peloton Interactive and Xcel…
The futures are positive after a strong risk-on Wednesday that saw all of the major indices close higher. The tailwind for stocks was provided by the June consumer-price-index numbers that saw inflation…
Thursday's top analyst upgrades and downgrades included Antero Resources, AutoZone, Coterra Energy, Dollar General, Eli Lilly, First Horizon, Infosys, Owens Corning, Palo Alto Networks, Range Resources, Southwestern Energy, Toast, Urban Outfitters and Workday.
Wednesday's top analyst upgrades and downgrades included Chevron, Cleveland-Cliffs, Infosys, Knight-Swift Transportation, Microsoft, Nucor, Salesforce, Steel Dynamics, Wheaton Precious Metals and Zoom Video Communications.
Wednesday’s additional top analyst upgrades and downgrades included Humana, Nvidia, Thor and more.
Thursday's top analyst upgrades and downgrades included AT&T, Boeing, ConocoPhillips, Gilead Sciences, Illumina, Lam Research, Raytheon Technologies and Yum Brands.
The top analyst upgrades, downgrades and initiations seen on Thursday included AbbVie, Agilent Technologies, Albermarle, Apple, Boeing, Cheniere Energy, First Solar, HCA, LabCorp, Lumber Liquidators and Teva Pharmaceutical.
A Credit Suisse analyst issued a broad new sector coverage for medical devices and related companies with strong Outperform ratings on Tuesday.
The top analyst upgrades, downgrades and initiations seen on Tuesday included Abbott Laboratories, Albermarle, Boston Scientific, BP, Embraer, Intuit, Marathon Oil and Norfolk Southern.
The top analyst upgrades, downgrades and other research calls from Monday include BlackRock, Capital One, Kroger, Nordstrom, Starbucks and Wells Fargo.
The top analyst upgrades, downgrades and other research calls from Tuesday include Abbott Labs, Delphi, Lululemon, Netflix, Nordstrom, Sirius XM, Disney and Windstream.
Argus likes Integra’s strong growth prospects and its ability to execute on acquisition and mergers that help move the company's needle on growth in revenue and earnings.
Jon C. Ogg Biotech and pharma companies were on the move Wednesday. A few of the smaller caps made tremendous gains on the day, while a couple of the major firms saw massive volume and…
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a global medical technology company focused on neurosurgery, tissue reconstruction, and specialized surgical fields.
The Wall Street consensus 12-month price target for IART is $18.38.
